DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Gordon A. Troup was elected Chairman of the Board at a meeting of the Board of Directors held following the Company’s 2011 Annual Meeting of Stockholders. Mr. Troup succeeds Carl J. Aschinger, Jr., who has served as a director of our Company since June 2004 and as Chairman of the Board since July 2007.
"Gordon is an innovative, forward-thinking leader and has been a positive influence for the Company since joining the Board, and I am very pleased that he succeeds me as Chairman," Mr. Aschinger said. "He has played an important role in helping evaluate our growth strategy and in guiding us during this pivotal period in our Company’s history. His experience will serve the Company well as Neoprobe continues its transformation into a pure-play specialty radiopharmaceutical development and commercialization entity."
"In my time with Neoprobe, I have witnessed the beginning of an evolution of an entrepreneurial company with a niche medical device business and development stage radiopharmaceuticals into a company poised to become a lead player in the radiopharmaceutical space," Mr. Troup said. "Carl’s leadership and stewardship are evident in the enormous accomplishments at Neoprobe during the last several years and I thank him for his tremendous contribution as we look forward to getting Lymphoseek® over the goal line of FDA approval."
Mr. Troup has served as a director of Neoprobe since July 2008 and as Vice Chairman of the Board since July 2010. He served as President of the Nuclear Pharmacy Services business at Cardinal Health, Inc. (Cardinal Health), a multinational medical products and services company, from January 2003 until his retirement in December 2007. Mr. Troup joined Cardinal Health in 1990 and was appointed Group President of Pharmaceutical Distribution and Specialty Distribution Services in 1999. Prior to joining Cardinal Health, Mr. Troup was employed for ten years by American Hospital Supply Corporation and three years by Zellerbach Paper, a Mead Company. Mr. Troup has a B.S. degree in Business Management from San Diego State University.
"Carl’s vision and leadership guided Neoprobe from a small bulletin board company into an exchange-listed company on the verge of commercial success. We are fortunate to have had his counsel and guidance during the last several years," said Dr. Mark Pykett, President and Chief Executive Officer of Neoprobe. "I have also enjoyed working with Gordon as an active director and look forward to his new role as Chairman as we continue to build the Neoprobe business."
About Neoprobe
Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company focused on development of precision diagnostics that enhance patient care and improve patient benefit. Neoprobe is actively developing and commercializing targeted agents aimed at the identification of occult (undetected) disease. The Company’s two lead radiopharmaceutical agent platforms – Lymphoseek® and RIGScan™ – are intended to help surgeons better identify and treat certain types of cancer. In achieving its goals, Neoprobe’s business model leverages collaborations and partnerships with world-class institutions, manufacturing concerns and distribution entities. Neoprobe’s strategy is to deliver superior growth and stockholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline programs through continued investment and selective acquisition or in-licensing of complementary technologies. For more information, please visit www.neoprobe.com.
The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.